ARCA Biopharma signs license agreement with University of Cincinnati

ARCA Biopharma has announced that it has entered into a license agreement with the University of Cincinnati for exclusive worldwide rights to a portfolio of US and international patents, which includes certain patents covering genetic markers for the Company’s lead drug candidate, Gencaro (bucindolol hydrochloride), which is being developed for the treatment of chronic heart failure. The licensed patents relate to genetic polymorphisms of adrenergic cardiac receptors which the ARCA believes provide the basis for exclusive worldwide development, use and commercialization of the genetic test which may indicate a patient’s likely response to Gencaro as a treatment for multiple cardiovascular disorders. The licensed patents had previously been the subject of an agreement between ACRA and the University of Cincinnati executed in December 2009.